DE60010113D1 - N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate - Google Patents

N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate

Info

Publication number
DE60010113D1
DE60010113D1 DE60010113T DE60010113T DE60010113D1 DE 60010113 D1 DE60010113 D1 DE 60010113D1 DE 60010113 T DE60010113 T DE 60010113T DE 60010113 T DE60010113 T DE 60010113T DE 60010113 D1 DE60010113 D1 DE 60010113D1
Authority
DE
Germany
Prior art keywords
guanidinalkylamid
production
pharmaceutical preparations
preparations containing
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60010113T
Other languages
English (en)
Other versions
DE60010113T2 (de
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Fahad Al-Obeidi
Armin Walser
James Ostrem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Application granted granted Critical
Publication of DE60010113D1 publication Critical patent/DE60010113D1/de
Publication of DE60010113T2 publication Critical patent/DE60010113T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60010113T 1999-10-30 2000-10-21 N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate Expired - Lifetime DE60010113T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (de) 1999-10-30 1999-10-30 N-Guanidinoalkylamide, Verfahren zu ihrer Herstellung, ihre Verwendung und pharmazeutische Zusammensetzungen, die sie enthalten
EP99121623 1999-10-30
PCT/EP2000/010395 WO2001032611A1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (2)

Publication Number Publication Date
DE60010113D1 true DE60010113D1 (de) 2004-05-27
DE60010113T2 DE60010113T2 (de) 2005-05-04

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60010113T Expired - Lifetime DE60010113T2 (de) 1999-10-30 2000-10-21 N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate

Country Status (32)

Country Link
US (2) US6472562B1 (de)
EP (2) EP1095933A1 (de)
JP (1) JP4658430B2 (de)
KR (1) KR100981593B1 (de)
CN (1) CN1249026C (de)
AR (1) AR026257A1 (de)
AT (1) ATE264837T1 (de)
AU (1) AU776797B2 (de)
BR (1) BR0015186A (de)
CA (1) CA2389412C (de)
CZ (1) CZ301855B6 (de)
DE (1) DE60010113T2 (de)
DK (1) DK1228039T3 (de)
EE (1) EE05168B1 (de)
ES (1) ES2220553T3 (de)
HK (1) HK1050673A1 (de)
HR (1) HRP20020372B1 (de)
HU (1) HUP0203627A3 (de)
IL (2) IL149209A0 (de)
ME (1) MEP54708A (de)
MX (1) MXPA02003805A (de)
NO (1) NO328016B1 (de)
NZ (1) NZ518607A (de)
PL (1) PL203859B1 (de)
PT (1) PT1228039E (de)
RS (1) RS50471B (de)
RU (1) RU2253651C2 (de)
SI (1) SI1228039T1 (de)
SK (1) SK286856B6 (de)
TR (1) TR200201181T2 (de)
WO (1) WO2001032611A1 (de)
ZA (1) ZA200203294B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1644401T3 (da) * 2003-07-04 2011-06-20 Lonza Ag Forbedret fremgangsmåde til fastfasesyntese
ES2597436T3 (es) 2007-09-28 2017-01-18 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
MY191407A (en) 2008-01-04 2022-06-27 Intellikine Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2364165B1 (de) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidote für faktor-xa-inhibitoren und verfahren zu ihrer verwendung in kombination mit blutgerinnungsmitteln
EP3121271B1 (de) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Gegenmittel für faktor-xa-hemmer und verfahren zur verwendung davon
EP2453910B1 (de) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Einzeldosisformulierung von antidoten für faktor-xa-hemmer zur prävention von blutung
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017223422A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN115317474A (zh) * 2021-05-10 2022-11-11 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994017635A1 (en) 1993-01-20 1994-08-04 Peter John Alexandrovics A line monitoring system
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
EP1384725A3 (de) 1994-04-26 2007-02-21 Aventis Pharmaceuticals Inc. Inhibitoren von Faktor Xa
AU688628B2 (en) * 1994-12-02 1998-03-12 Yamanouchi Pharmaceutical Co., Ltd. Novel amidinonaphthyl derivative or salt thereof
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
KR20010023364A (ko) * 1997-08-27 2001-03-26 간자와 무츠와 3-아미디노아닐린 유도체, 활성화 혈액응고 제 ｘ 인자저해제 및 그것의 제조중간체
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
RU2225397C2 (ru) 1997-12-24 2004-03-10 Авентис Фарма Дойчланд Гмбх Производные индола как ингибиторы фактора Ха
WO1999037643A1 (fr) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques a fusion benzenique ou sels de ceux-ci
EP0987274A1 (de) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
US6348482B1 (en) * 1999-05-05 2002-02-19 Merck & Co., Inc. Catechols as antimicrobial agents

Also Published As

Publication number Publication date
NZ518607A (en) 2003-10-31
HUP0203627A3 (en) 2004-12-28
US6664393B2 (en) 2003-12-16
US6472562B1 (en) 2002-10-29
HK1050673A1 (en) 2003-07-04
PL203859B1 (pl) 2009-11-30
SI1228039T1 (en) 2004-10-31
CN1249026C (zh) 2006-04-05
AU1026501A (en) 2001-05-14
CA2389412A1 (en) 2001-05-10
YU29702A (sh) 2005-06-10
TR200201181T2 (tr) 2002-09-23
JP2003513066A (ja) 2003-04-08
MXPA02003805A (es) 2004-10-15
KR100981593B1 (ko) 2010-09-13
KR20020047310A (ko) 2002-06-21
ZA200203294B (en) 2003-01-29
EE05168B1 (et) 2009-06-15
AR026257A1 (es) 2003-02-05
DK1228039T3 (da) 2004-08-16
DE60010113T2 (de) 2005-05-04
IL149209A (en) 2007-06-03
PT1228039E (pt) 2004-09-30
MEP54708A (en) 2011-05-10
CZ301855B6 (cs) 2010-07-14
CA2389412C (en) 2009-12-01
ATE264837T1 (de) 2004-05-15
HRP20020372B1 (en) 2011-01-31
RU2253651C2 (ru) 2005-06-10
CN1387508A (zh) 2002-12-25
HUP0203627A2 (hu) 2003-03-28
EP1228039A1 (de) 2002-08-07
BR0015186A (pt) 2002-07-23
EP1095933A1 (de) 2001-05-02
NO328016B1 (no) 2009-11-09
IL149209A0 (en) 2002-11-10
SK286856B6 (sk) 2009-06-05
NO20022022L (no) 2002-04-29
SK5782002A3 (en) 2002-10-08
RU2002114041A (ru) 2004-01-20
CZ20021489A3 (cs) 2002-07-17
US20030162967A1 (en) 2003-08-28
NO20022022D0 (no) 2002-04-29
AU776797B2 (en) 2004-09-23
ES2220553T3 (es) 2004-12-16
HRP20020372A2 (en) 2004-08-31
PL354808A1 (en) 2004-02-23
EP1228039B1 (de) 2004-04-21
JP4658430B2 (ja) 2011-03-23
EE200200199A (et) 2003-06-16
WO2001032611A1 (en) 2001-05-10
RS50471B (sr) 2010-03-02

Similar Documents

Publication Publication Date Title
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE248811T1 (de) Indanylsubstituierte benzolcarbonamide, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
DE69811735T2 (de) Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
DE69723571D1 (de) Methyliden-malonat nanopartikel, verfahren zu deren herstellung, und diese enthaltende pharmazeutische praeparate
DE69902535D1 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE215951T1 (de) Tetracyclische campothecineanalogue, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
ATE279392T1 (de) Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
DE50013167D1 (de) 2'-substituierte 1,1'-biphenyl-2-carboxamide, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
ATE294175T1 (de) 4-sulfonamid-piperidin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
DE69909209D1 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
ATE337317T1 (de) Imidazopyrin-derivate, verfahren zu ihrer herstellung and sie enthaltende pharmazeutische zusamensetzungen
DE60036102D1 (de) Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE60010113D1 (de) N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
DE60013463D1 (de) Pharmazeutische produkte und verfahren zu deren herstellung
ATE354356T1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
ATE241637T1 (de) Pentasaccharide, verfahren zu ihrer herstellung und pharmazeutische zubereitungen die sie enthalten
ATE222586T1 (de) Benzolsulfonamidderivate und verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE60123292D1 (de) Uht-milchkonzentratspackung und verfahren zu ihrer herstellung
DE60003662D1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE60022890D1 (de) Naphthyridine derivate, verfahren zu ihrer herstellung, deren anwendung und sie enthaltende pharmazeutische zusammensetzungen
ATE275136T1 (de) Morpholinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE370942T1 (de) (1-phenacyl-3-phenyl-3- piperidylethyl)piperidinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE250051T1 (de) Sulfonamid-substituierte benzopyranderivate, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
DE69924527D1 (de) Arylalkanoylderivate, verfahren zu ihrer herstellung, ihre verwendung und diese enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,